After navigating a challenging funding landscape in 2025, the UK biotech sector appears to be in recovery, as per data from the BioIndustry Association (BIA).
This comes as UK financing hit a five-year high in the second quarter of 2026, with the portion of equity financing raised by British biotechs hitting £2.11bn ($2.84bn), of which a record £2.05bn was venture capital (VC).
One of the landmark British financings in Q2 was Isomorphic Lab’s mega-round, which saw the London-based company secure £1.6bn ($2.1bn) to deploy its artificial intelligence (AI)-powered drug design platform and progress its pipeline of therapies to the clinic. However, Isomorphic was not the only success story, as the £498m total raised by other UK biotechs nearly doubled the same portion raised back in Q2 2025.
This uptick in private biotech financing builds on the early signs of success in Q1, in which equity financing and VC raises saw a notable uptick from the final quarter of 2025.
Much like Q1, UK biotech's financing success was primarily seen in the private sector, with modest improvements observed in the public markets. During Q2, follow-on financing hit £58m, marking a 61% increase from the £36m in Q1 and more than tripling the £15m value raised in Q2 2025. However, no UK biotechs have filed for an IPO thus far, and there has been little activity from UK biotech companies with a Nasdaq listing.
The BIA debuts these Q2 figures as some British industry figures warn that the challenges they face in accessing finance could dull the UK’s competitive edge, which they said represented the most urgent barrier to growth at a recent industry roundtable.
Despite the ongoing challenges, the Q2 financing landscape still proves that the UK holds ‘small but mighty’ potential as a key player in the European market, with British biotechs garnering 61% of the £3.3bn of total VC raised by Europe within the quarter.
Looking ahead: future prospects for British biotech
With mixed sentiments on the UK’s biotech overall competitiveness on the global stage, BIA’s CEO, Chris Molloy, remains optimistic for the future – noting that a “continued improvement in funding confidence and deal flow” has seen British companies secure fundraising “from seed to Series D at world-class valuations.”
With this in mind, Molloy believes it’s now crucial that UK biotechs offer proven returns to investors to attract them back to the sector.
Previously, the BIA’s director of policy and external affairs, Martin Turner, told Pharmaceutical Technology that policies aimed at incentivising pension providers to invest in UK biotech and pharma will pave the way for future growth, as well as the creation of a favourable tax environment for business to attract manufacturing and commercial operations.
Molloy echoed this sentiment, stating that the UK public markets “need to recognise, cover and return to backing our sector”.
“Private momentum must be joined by robust, public sector-managed, investor-advised translational funding. This combination will de-risk the early-to-mid stage companies and sustain growth across every tier of the sector, making the whole of the UK fit to fund,” Molloy concluded.
